Brexogen, a biotechnology company specializing in exosome-based therapeutics, has signed a technology transfer and licensing agreement with BMI Korea. This agreement marks the first major licensing deal for an exosome therapeutic in Korea, highlighting the growing interest and potential of exosome-based medicines in the region.

BxC-I17e, a key asset in Brexogen’s pipeline, is currently undergoing clinical trials in the United States for atopic dermatitis. Recognizing its broader therapeutic potential, BMI Korea has acquired the rights to expand the development of BxC-I17e into potential indications beyond immunological indications, encompassing both domestic and key export markets.

While the financial terms of the agreement remain confidential, Brexogen will receive a non-refundable upfront payment of KRW 3 billion (approximately USD 2.3 million). Additionally, milestone payments will be linked to clinical, regulatory, and commercial progress, and Brexogen will earn double-digit percentage royalties on annual net sales. Furthermore, Brexogen will share in future licensing revenues should BMI Korea pursue further out-licensing agreements with third parties.

BMI Korea, a leading company in prescription drugs, biologics, medical devices, and aesthetic products, has extensive expertise in contract manufacturing (CMO) facilities in Jeju and Osong, Chungbuk. These facilities provide a robust infrastructure for regulatory approvals, production, and commercialization of pharmaceutical products.

Under this partnership, BxC-I17e will be manufactured at BMI Korea’s facilities, ensuring scalability for both clinical and commercial supply. This collaboration will facilitate the efficient production and distribution of BxC-I17e, contributing to its successful commercialization in Korea and beyond.

“Partnering with BMI Korea is a significant step forward for Brexogen,” said a Brexogen representative. “Their robust pharmaceutical manufacturing expertise provides a strong foundation for the commercialization of BxC-I17e, allowing us to accelerate market entry while ensuring high-quality production.”

A BMI Korea spokesperson added: “This agreement positions BMI Korea as a leader in exosome-based therapeutics. By securing one of the most advanced pipelines in the industry, we are poised to achieve Korea’s first regulatory approval for an exosome therapy and expand our biopharmaceutical portfolio.”

To date, globally, there is no approved exosome-based therapeutics for commercial use. This partnership is expected to accelerate the clinical and commercial adoption of exosome-based therapeutics, paving the way for groundbreaking advancements in regenerative medicine.